PPA
MRSN

Parametric Portfolio Associates’s Mersana Therapeutics MRSN Stock Holding History

Parametric Portfolio Associates’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$119K Buy
1,193
+10
+0.8% +$1.17K ﹤0.01% 3534
2021
Q4 		$184K Sell
1,183
-160
-12% -$31.1K ﹤0.01% 3442
2021
Q3 		$317K Sell
1,343
-96
-7% -$28K ﹤0.01% 3278
2021
Q2 		$489K Sell
1,439
-153
-10% -$57.9K ﹤0.01% 3094
2021
Q1 		$644K Buy
1,592
+678
+74% +$329K ﹤0.01% 3373
2020
Q4 		$608K Buy
914
+120
+15% +$66.7K ﹤0.01% 3291
2020
Q3 		$370K Sell
794
-3
-0.4% -$1.52K ﹤0.01% 3401
2020
Q2 		$466K Buy
797
+213
+36% +$72.7K ﹤0.01% 3309
2020
Q1 		$85K Buy
584
+50
+9% +$8.74K ﹤0.01% 3753
2019
Q4 		$76K Sell
534
-1,795
-77% -$131K ﹤0.01% 3891
2019
Q3 		$92K Sell
2,329
-2,586
-53% -$188K ﹤0.01% 3845
2019
Q2 		$498K Buy
4,915
+214
+5% +$25.2K ﹤0.01% 3367
2019
Q1 		$618K Buy
4,701
+78
+2% +$9.81K ﹤0.01% 3243
2018
Q4 		$472K Buy
4,623
+2,038
+79% +$322K ﹤0.01% 3338
2018
Q3 		$646K Buy
2,585
+821
+47% +$275K ﹤0.01% 3315
2018
Q2 		$787K Buy
1,764
+365
+26% +$160K ﹤0.01% 3166
2018
Q1 		$552K Buy
1,399
+457
+49% +$180K ﹤0.01% 3293
2017
Q4 		$387K Buy
942
+1
+0.1% +$436 ﹤0.01% 3450
2017
Q3 		$407K Buy
+941
New +$371K ﹤0.01% 3542

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Parametric Portfolio Associates's MRSN Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Mersana Therapeutics (MRSN) stake by 0.85% in Q1 2022, buying an estimated $1.17K and bringing the position to 1,193 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3534.

Parametric Portfolio Associates first reported a position in MRSN in Q3 2017 and has held it in 19 quarters since. The position peaked at $787K in Q2 2018. 129 funds tracked by Wall St. Rank hold MRSN as of Q1 2022.

  • Parametric Portfolio Associates held 1,193 shares of Mersana Therapeutics worth $119K as of Q1 2022.
  • Parametric Portfolio Associates bought 10 Mersana Therapeutics shares in Q1 2022, an estimated $1.17K.
  • Mersana Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3534 holding.
  • Parametric Portfolio Associates first reported a position in Mersana Therapeutics in Q3 2017 and has held it in 19 quarters since.
  • Parametric Portfolio Associates's Mersana Therapeutics position peaked at $787K in Q2 2018.
  • 129 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.